Treatment with an anti-IGF1R antibody in mouse xenografts of osteosarcoma showed promising results [55], and this preclinical evaluation provided motivation for a phase II clinical trial testing an anti-IGF1R antibody in combination with mTOR inhibitor in several sarcomas [56]. This evidence concerns the gene IGF1R and sarcoma.